|
|
|
|
Science Sparks @ ACTREC
|
 17 August 2026 |
Vol. No. 15 ; Issue No.748 |
|
|
Publications
|
|
1. Panigrahi G, Gandhi K, Joshi A, Dash S, Jadhav S, Gupta S, Yadav S, Jiwnani S, Sharma D, Sandur S, Gota V (2026). Mitocurcumin disrupts glutathione balance by modulating Klf9/GSR axis to overcome platinum resistance in non-small cell lung cancer and restores immune surveillance in cold tumor. Free Radical Biology and Medicine.
2. Trikha M, Rath S, Ventrapati P, Bhargava P, Siddiqui A, Pawar A, Patil P, Krishnamurthy R, Sahay A, Popat P, Haria P, Shah S, Kapu V, Sekar A, Pathak R, Joshi S, Wadasadawala T, Sarin R, Badwe R, Gupta S, Bajpai J (2026). Self-Reported Compliance with Adjuvant Endocrine Therapy in Young Women with Hormone Receptor-Positive Early Breast Cancer: A Real-World Study from a Tertiary Cancer Centre in India. Clinical Breast Cancer
|
|
|
|
|
|
|
Video of the Week
|
|
| Imaging and Technological Advances in Clinical Radiation Oncology
|
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2004, Azacitidine, an inhibitor of DNA methylation and a pioneering epigenetic therapy, became the first drug to gain US Food and Drug Administration (FDA) approval for the treatment of myelodysplastic syndrome.
|
|
|
|
Cancer News
|
| |
|
Researchers discover a potential weak spot in one of the deadliest brain cancers
|
|
SciTechDaily, 15/08/2026
|
|
The researchers focused on PP2A, an enzyme that regulates signals involved in cancer cell growth, survival, and repair after treatment. Glioblastoma cells appear to suppress PP2A using three proteins called ANP32A, CIP2A, and SET. When the researchers blocked these proteins in laboratory and animal models,...
|
| |
|
|
|
|
| |
|
|
|
Study uncovers hidden switch that helps cancer cells to evade immune detection
|
|
News-Medical, 13/08/2026
|
|
The discovery identifies a novel mechanism of cancer immune evasion and highlights DDX6 as a potential new target for cancer immunotherapy. Targeting this pathway could help overcome cancer-associated immunosuppression and potentially improve the effectiveness of existing cancer immunotherapies...
|
|
|
|
|
|
|
|
|
2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
